INTRODUCTION
============

Coronary artery disease (CAD), a common manifestation of atherosclerosis, is responsible for a high percentage of morbidity and mortality in the Western world \[[@B1]\]. A large body of evidence supports the idea that inflammatory mechanisms play an important role throughout all phases of atherogenesis, from the formation of fatty streaks to the acute coronary event due to vulnerable plaque rupture \[[@B1]-[@B3]\]. Smooth muscle cells produce extracellular matrix (ECM), leading to the formation of the fibrous cap that covers the atheromatic plaque \[[@B4]\]. Conversely, proteases with collagenolytic properties counterbalance collagen synthesis. ECM degradation is mainly achieved through the action of matrix metalloproteinases (MMPs), a family of zincand calcium-dependent endopeptidases and macrophages proposed to be the main contributors of MMPs within the atherosclerotic plaque \[[@B5],[@B6]\]. Interleukin (IL)-6, tumor necrosis factor-α, and IL-1β increase the expression of MMPs \[[@B7],[@B8]\], whereas cytokines that exert atheroprotective actions reduce MMP production \[[@B9]\]. Among the MMPs, MMP-9 is highly expressed in the vulnerable regions of the atherosclerotic plaque and has been suggested to be causally involved in plaque rupture \[[@B10]\]. Plasma MMP-9 concentrations are elevated in patients with acute myocardial infarction (MI) \[[@B11]-[@B13]\]. Endogenous MMP activity is regulated by the tissue inhibitors of matrix metalloproteinase (TIMP), in particular TIMP-1, which binds to several MMPs with high affinity \[[@B14],[@B15]\].

Several cytokines exert anti-inflammatory and atheroprotective actions. IL-33 is expressed in coronary artery smooth muscle cells \[[@B16]\], coronary artery endothelium \[[@B17]\], nonhigh endothelial venule endothelial cells \[[@B18]\], and cardiac fibroblasts, suggesting that IL-33 may play a role in various cardiovascular disorders \[[@B19]\]. In addition, IL-33 markedly increases levels of IL-4, -5, and -13, but decreases interferon (IFN)-γ levels in serum and lymph node cells. IL-33 may play a protective role in the development of atherosclerosis via the induction of IL-5 and oxidized low density lipoprotein (ox-LDL) antibodies \[[@B20]\]. The immunological response of Th1 type and its mediators (i.e., IFN-γ) is believed to accelerate atherosclerosis, whereas the response of Th2 type and its mediators (i.e., IL-4, IL-5, and IL-13) inhibit the development of atherosclerosis \[[@B20]-[@B23]\]. IL-33 reduces MMP release by intentionally decreasing IFN-γ levels having inflammatory effects and inhibits plaque rupture.

The correlation between the time course of serum concentration changes in IL-33, MMP-9, and TIMP-1 and the extent of acute coronary syndrome (ACS) during and after acute MI is unclear. Therefore, in the present study, we evaluated the serum concentrations of these markers at various time points in patients with ACS.

METHODS
=======

Patients
--------

The study population was composed of 55 patients with complaints of sudden chest pain who were admitted to the emergency department within the first 6 hours of pain onset. Exclusion criteria were as follows: a diagnosis of renal failure, collagen tissue disease, infection, vasculitis, depression, or somatization or having undergone angioplasty, bypass surgery, or open-heart surgery. The patient group was divided into two subgroups: patients with unstable angina (UA; n = 25) and those with non-ST elevated myocardial infarction (NSTEMI; n = 30). The leading symptom of ACS is typically chest pain. The working diagnosis of NSTEMI-ACS is a rule-out diagnosis based on the electrocardiogram showing a lack of persistent ST elevation. Biomarkers (troponins) further distinguish NSTEMI and UA \[[@B24]\]. The control group consisted of 25 patients who had no significant coronary artery stenosis (25% of luminal diameter) and were age- and sex-matched with the patient groups. The study was performed in compliance with the Declaration of Helsinki.

Venous blood samples were obtained when patients with NSTEMI were admitted to our hospital. Postadmission blood samples were obtained at 12, 24, and 48 hours after percutaneous coronary intervention. Blood samples were obtained from the control group in the morning. Triglycerides, total cholesterol, high density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP), fibrinogen, troponin I, aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and isoenzymes of phosphocreatine kinase (creatine kinase-MB, CK-MB) were measured immediately. For other measurements, the blood samples were centrifuged at 1,500 ×g and 4℃ for 10 minutes and stored at -86℃ until analysis. Blood samples were drawn on admission and at 12, 24, and 48 hours after the onset of infarction for measuring MMP-9, TIMP-1, and IL-33 levels.

MMP-9 measurement
-----------------

The concentrations of MMP-9 were determined in duplicate using the RayBio enzyme-linked immunosorbent assay (ELISA) kits (RayBiotech Inc., Norcross, GA, USA) designed to measure their pro and active forms. The detection limit of this assay was 10 pg/mL. Intra and interassay variations were less than 12%.

IL-33 measurement
-----------------

IL-33 levels were determined using the ELISA Kit (USCN Life Science Inc., Houston, TX, USA). A monoclonal antibody specific for IL-33 was precoated onto a microplate. The detection limit of this assay was less than 6.4 pg/mL.

TIMP-1 measurement
------------------

The concentrations of TIMP-1 were determined in duplicate using the RayBio ELISA kits (RayBiotech Inc.). The detection limit of this assay was 40 pg/mL. Intra and interassay variations were less than 12%.

Others assays
-------------

For the CRP measurement, the particle-enhanced immunoturbidimetric method was performed using a Behring Nephelometer BN-100 (Behring Diagnostic, Frankfurt, Germany). The sensitivity of the test was 0.1 mg/L.

Serum cholesterol, triglyceride, and HDL-C were measured using enzymatic colorimetric methods with commercially available kits (Cobas 311, Roche Diagnostics GmbH, Mannheim, Germany) and LDL-C was calculated according to the Friedewald formula. Serum glucose levels were determined enzymatically by the hexokinase method (Roche Diagnostics GmbH).

Cardiac troponin T (cTnT) was measured by an electrochemiluminescence immunoassay (Troponin T, Roche Diagnostics GmbH) using an Elecsys E170 analyzer (Roche Diagnostics GmbH). The lower limit of detection for the cTnT assay was 3 ng/L. Serum CK-MB, AST, and LDH levels were determined in a Roche/Cobas 311 automated clinical chemistry analyzer. Fibrinogen levels were determined by the Clauss method using Multifibren U (Dade Behring, Marburg, Germany), and leukocyte levels were measured with an automatic hematology analyzer (Beckman Coulter, Brea, CA, USA).

Statistical analysis
--------------------

Statistical analyses were performed with a IBM SPSS version 18.0 package (IBM, Armonk, NY, USA). Values were expressed as means ± SD. The significance of the mean differences between groups was assessed by a Mann-Whitney and Student\'s *t* test. Relationships between variables were tested using Pearson\'s correlation analysis. The *p* values less than 0.05 were considered statistically significant.

RESULTS
=======

No significant differences were observed between patients with ACS and the healthy control group with respect to age. As shown in [Table 1](#T1){ref-type="table"}, when compared with the UA and control groups, serum MMP-9 levels were significantly higher in the NSTEMI group on admission (*p* \< 0.01, *p* \< 0.05, respectively). Additionally, MMP-9 levels were significantly higher in the UA group compared to the control group (*p* \< 0.05) ([Table 1](#T1){ref-type="table"}). TIMP-1 levels were significantly higher in the NSTEMI group than either the UA or control groups (*p* \< 0.05). The UA group had significantly lower TIMP-1 levels (*p* \< 0.05) than the MI group ([Table 1](#T1){ref-type="table"}). IL-33 levels were significantly lower in the NSTEMI group compared to the control group (*p* \< 0.05) ([Table 1](#T1){ref-type="table"}).

As for enzymes indices, the NSTEMI group had significantly higher CK-MB, AST, and LDH levels (*p* \< 0.01, *p* \< 0.001, *p* \< 0.01, respectively) than the control group. A comparison between the NSTEMI and UA groups revealed significantly higher CK-MB and AST levels (*p* \< 0.01, *p* \< 0.05, respectively) in the NSTEMI group ([Table 1](#T1){ref-type="table"}). In addition, CK-MB and AST levels were significantly higher in the UA group compared to the control group (*p* \< 0.05 for both) ([Table 1](#T1){ref-type="table"}).

As for inflammatory parameters, the NSTEMI group had significantly higher CRP, fibrinogen, and leukocyte count levels (*p* \< 0.05, *p* \< 0.01, *p* \< 0.05, respectively) than the control group. A comparison between the NSTEMI and UA groups revealed significantly higher leukocyte count levels (*p* \< 0.05) in the NSTEMI group ([Table 1](#T1){ref-type="table"}). In addition, fibrinogen and leukocyte count levels were significantly higher in the UA group compared to the control group (*p* \< 0.05) ([Table 1](#T1){ref-type="table"}).

When compared to the control group, the NSTEMI group had significantly higher triglyceride and total cholesterol levels (*p* \< 0.05). In addition, HDL-C levels were significantly lower in the NSTEMI patient group compared to the control group (*p* \< 0.05). A comparison of the NSTEMI and UA patient groups revealed significantly higher triglyceride levels (*p* \< 0.05) in the NSTEMI group ([Table 1](#T1){ref-type="table"}).

[Table 2](#T2){ref-type="table"} shows the time course changes in the serum MMP-9, TIMP-1, and IL-33 concentrations after NSTEMI. The MMP-9 levels on admission were significantly higher than those observed at 24 and 48 hours (*p* \< 0.05). The MMP-9 level at 12 hours was significantly higher than that at 48 hours (*p* \< 0.05). The serum TIMP-1 level on admission was significantly lower than the level at 48 hours (*p* \< 0.05), whereas the level of IL-33 on admission was significantly lower than the level at 12 hours (*p* \< 0.05) ([Table 2](#T2){ref-type="table"}).

Significant positive correlations were observed between MMP-9 and TIMP-1, CRP, and LDH levels (*r* = 0.307, *p* \< 0.01 and *r* = 0.321, *p* \< 0.05 and *r* = 0.387, *p* \< 0.01, respectively). MMP-9 levels were negatively correlated with IL-33 levels (*r* = -0.461, *p* \< 0.05). TIMP-1 levels were positively correlated with both CRP and leukocyte count levels (*r* = 0.394, *p* \< 0.05 and *r* = 0,420, *p* \< 0.05, respectively) and negatively correlated with IL-33 levels (*r* = -0.288, *p* \< 0.05). IL-33 levels were negatively correlated with CRP levels (*r* = -0.441, *p* \< 0.05) ([Table 3](#T3){ref-type="table"}).

DISCUSSION
==========

MMP, an ECM-degrading enzyme, plays a crucial role in the breakdown of the fibrous cap of plaque and subsequent rupture in the pathogenesis of ACS \[[@B25]\]. MMP-9 affects plaque stability in association with various inflammatory cytokines \[[@B26]\].

The results of this study indicate that the serum levels of the inflammatory marker MMP-9, CRP, and leukocyte count were significantly higher at the acute phase of patients with either NSTEMI or UA. Patients with NSTEMI had higher levels of MMP-9 and a higher leukocyte count compared to patients with UA. These findings provide evidence that both NSTEMI and UA are accompanied by an increased inflammatory process. Our observation showing elevated serum levels of MMP-9 in subjects with acute MI is consistent with published data \[[@B11],[@B12],[@B27],[@B28]\]. Several studies have demonstrated that plasma levels of MMP-9 are significantly higher in the coronary artery than in the systemic circulation of patients with acute MI \[[@B11],[@B29]\]. Thus, the atherosclerotic plaque may be the major source of MMP-9 released into the circulation \[[@B13]\].

TIMP-1 is a major inhibitor of MMP-9 \[[@B15]\]. In our study, serum levels of TIMP-1 were increased in both UA and NSTEMI groups. Patients with NSTEMI had higher levels of TIMP-1 compared to patients with UA. Controversial findings are reported in the literature regarding the levels of TIMP-1 in patients with NSTEMI. Some studies have reported a decrease in TIMP-1 levels in patients with acute MI \[[@B30]\], while others have described elevated levels of TIMP-1 in patients with acute MI \[[@B29],[@B31],[@B32]\]. In a report by Inokubo et al. \[[@B33]\], elevated levels of TIMP-1 during acute MI were demonstrated only in blood taken from the coronary sinus, but not in aortic blood; this observation was attributed to the release from the ruptured atherosclerotic plaque.

We examined a time course series of plasma-level changes of MMP-9 and TIMP-1 (on admission, and at 12, 24, 48, and 72 hours after admission). Serum levels of MMP-9 and TIMP-1 were found to be the highest at the onset of NSTEMI. The MMP-9 level gradually decreased and reached its lowest value at 48 hours. The MMP-9 levels on admission were significantly higher when compared to the blood samples collected at 24 and 48 hours. The MMP-9 level at 12 hours was significantly higher than the level at 48 hours. In contrast, the TIMP-1 level on admission gradually increased and reached its highest value at 72 hours. However, our results show that the atherosclerotic plaque is not the only source from which MMP-9 is released: it may be released from the interstitium of the ischemic myocardium in the early period as well after an NSTEMI. TIMP-1 has been shown to be upregulated after NSTEMI and to be released as a response to prevent any damage that might occur in the matrix due to the sudden increase in the MMP-9 levels at the onset of NSTEMI.

Kai et al. \[[@B12]\] found that plasma MMP-9 levels on day 0 were about 3-fold and 2-fold higher in the UA group than in the control and EA groups, respectively. Tziakas et al. \[[@B34]\] found similar results as ours regarding the alterations in the MMP-9 and TIMP-1 levels at 24 and 72 hours. Etoh et al. \[[@B13]\] demonstrated increased expression of soluble interstitial MMP-9 as early as 2 hours after onset of the infarction. Kaden et al. \[[@B28]\] found the plasma concentration of MMP-9 was elevated in patients with acute MI and showed a rapid normalization to baseline levels within 1 week.

In the present study, significantly positive correlations were observed between MMP-9 and TIMP-1, CRP, and LDH levels. TIMP-1 levels were positively correlated with both CRP and leukocyte count levels. Kalela et al. \[[@B27]\] found a positive correlation between serum MMP-9 and leukocyte count in healthy subjects. MMP-9 levels were closely correlated with the release of creatinine kinase as a marker of myocardial damage \[[@B29]\]. TIMP-1 was strongly correlated with CRP \[[@B35]\]. Tan et al. \[[@B36]\] observed significant and positive correlations between MMP-9 and TIMP-1. Thus, these data show that TIMP-1, in response to the activation of MMP-9, plays a protective role during the early phase of NSTEMI.

Although recent studies have reported alterations in MMP-9 and TIMP-1 levels in the early stages of NSTEMI, no study has reported alterations in IL-33 levels in the early stages of NSTEMI. Therefore, the present study is the first to demonstrate the relationship between levels of IL-33 and levels of MMP-9, TIMP-1, and CRP and leukocyte count in the early stages of NSTEMI.

The IL-33 decoy receptor sST2 was shown to be elevated in serum early after acute MI \[[@B37]\]. IL-33 treatment increased levels of the Th2 cytokines IL-4, IL-5, and IL-13, but decreased levels of the Th1 cytokine IFN-γ in serum \[[@B38]\]. In the atheromatous plaque, proinflammatory factors produced by T lymphocytes (e.g., IFN-γ) seem to play a crucial role \[[@B21],[@B39],[@B40]\]. These cytokines decrease the production of the ECM by smooth muscles, and at the same time, they increase the production of the metalloproteinases by macrophages \[[@B40]\]. For this reason, IL-33 has a defensive role against MMP activation and ECM destruction by inhibiting IFN-γ release.

The results of this study indicate that serum levels of IL-33 also increased in the NSTEMI group compared to the control group. We examined the time course changes of the plasma soluble IL-33 levels (on admission, and at 12, 24, and 48 hours after NSTEMI). We showed that the IL-33 levels on admission were significantly lower than those detected in the blood samples collected at 12 hours. Thus, we speculate that IL-33, following the activation of IL-33, plays a protective role during the early phase of NSTEMI. IL-33 levels were negatively correlated with MMP-9, TIMP-1, and CRP levels.

In conclusion, the results presented here suggest that the determination of serum MMP-9 and TIMP-1 could represent a sensitive marker of inflammation in patients with NSTEMI. However, the endothelial cells of patients with NSTEMI seem to have an increased response to this inflammatory stimulus, leading to higher levels of MMP-9 and a higher degree of endothelial cell injury accompanied by the release of lower levels of IL-33 when compared to both the UA and control groups. Nevertheless, we believe that combined measurement of MMP-9, TIMP-1, and IL-33 with other well-known markers of inflammation, such as CRP, might provide an index of plaque activity in NSTEMI and may prompt future investigations addressing the predictive role of MMP-9, TIMP-1, and IL-33 in the definition of the risk of acute coronary events in patients with CAD.

One limitation of this study was the small number of subjects (a total of 80 in the three groups). Another limitation was the absence of a ST MI group.

KEY MESSAGE
===========

1\. Elevated levels of matrix metalloproteinase (MMP)-9 and decreased levels of interleukin (IL)-33 and tissue inhibitor of MMP-1 play a role in the development and progression of myocardial infarction.

2\. Decreased IL-33 levels may play a major role in the process that terminates in plaque rupture, thrombus formation, and an acute coronary syndrome.
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###### 

Values and statistical significance of the analyzed parameters in the NSTEMI, UA, and control groups

![](kjim-28-165-i001)

Values are presented as mean ± SD.

NSTEMI, non-ST elevated myocardial infarction; UA, unstable angina; M, male; F, female; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; CRP, C-reactive protein; CK-MB, creatine kinase-MB; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; MMP-9, matrix metalloproteinase-9; TIMP-1, tissue inhibitor of matrix metalloproteinase-1; IL-33, interleukin-33.

^a^Between NSTEMI and control groups, *p* \< 0.05.

^b^Between NSTEMI and UA groups, *p* \< 0.05.

^c^Between NSTEMI and control groups, *p* \< 0.01.

^d^Between UA and control groups, *p* \< 0.05.

^e^Between NSTEMI and control groups, *p* \< 0.001.

^f^Between NSTEMI and UA groups, *p* \< 0.001.

^g^Between NSTEMI and UA groups, *p* \< 0.01.

###### 

Time course of changes in MMP-9, TIMP-1, and IL-33 after NSTEMI

![](kjim-28-165-i002)

Values are presented as mean ± SD.

MMP-9, matrix metalloproteinase-9; TIMP-1, tissue inhibitor of matrix metalloproteinase-1; IL-33, interleukin-33; NSTEMI, non-ST elevated myocardial infarction.

^a^0 to 24 hr, *p* \< 0.05.

^b^0 to 48 hr, *p* \< 0.05.

^c^12 to 48 hr, *p* \< 0.05.

^d^0 to 12 hr, *p* \< 0.05.

###### 

Correlations among MMP-9, TIMP-1, and IL-33 in NSTEMI

![](kjim-28-165-i003)

MMP-9, matrix metalloproteinase-9; TIMP-1, tissue inhibitor of matrix metalloproteinase-1; IL-33, interleukin-33; NSTEMI, non-ST elevated myocardial infarction; CRP, C-reactive protein; CK-MB, creatine kinase-MB; AST, aspartate aminotransferase; LDH, lactate dehydrogenase.

^a^*p* \< 0.05.

^b^*p* \< 0.01.
